Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Harvard Business School
Express Scripts
Federal Trade Commission
Fish and Richardson

Generated: March 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,664,225

« Back to Dashboard

Title:1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition
Abstract: The use of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in the treatment of pain and residual symptoms in depression is provided. ##STR00001##
Inventor(s): Moore; Nicholas (Delmar, NY), Stensbol; Tine Bryan (Vaerlose, DK)
Assignee: H. Lundbeck A/S (Valby-Copenhagen, DK)
Filing Date:Mar 14, 2008
Application Number:12/527,911
Claims:1. A method for the treatment of pain, the method comprising the administration of a therapeutically effective amount of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine or a pharmaceutically acceptable acid addition salt thereof (compound I) to a patient in need thereof.

2. The method according to claim 1, wherein compound I is the HBr acid addition salt.

3. The method according to claim 2, wherein said HBr acid addition salt is crystalline with XRPD reflections at 6.89, 9.73, 13.78 and 14.64 (.degree. 2.theta.).

4. The method according to claim 3, wherein said HBr acid addition salts has an XRPD as depicted in FIG. 3.

5. The method according to claim 1, wherein compound I is administered in daily doses of about 1-20 mg.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Express Scripts
Daiichi Sankyo
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.